Business Context and Reporting Period
This Form 8-K was filed by Conversion Labs, Inc. (noted as Lifemd, Inc. in metadata) on November 19, 2020. The filing reports the consummation of the second and final closing of a private placement offering.
Key Financial Metrics
- Transaction Type: Private placement of common stock.
- Shares Issued (Final Closing): 323,892 shares of common stock.
- Purchase Price (Final Closing): $1,538,487.00.
- Net Proceeds (Final Closing): Approximately $1.43 million.
- Total Aggregate Gross Proceeds (Entire Offering): $16,000,000.
- Placement Agent Compensation: 6% of the purchase price in cash plus warrants.
- Warrants Issued to Agent: 9,717 warrants at an exercise price of $4.75 per share, expiring November 19, 2025.
Material Changes
The filing details the completion of a capital raise. The company entered into a Securities Purchase Agreement and a Registration Rights Agreement with an accredited investor. Additionally, the company agreed to a 90-day lock-up period from the closing date, restricting the issuance of new common stock or equivalents with specific exemptions.
Outlook, Risks, and Management Commentary
- Registration Rights: The company is obligated to file a Form S-1 registration statement within 15 business days of the closing date and have it declared effective within 60 days (or 120 days if subject to full SEC review).
- Exemptions: Securities were sold in reliance on Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.
- Unusual Items: The filing notes that the Placement Agent received warrants exercisable on a "cashless" basis.
Investor Verification Checklist
- Verify the total capital raised ($16 million) against the company's current cash position and burn rate.
- Confirm the dilution impact of the 323,892 shares issued in this closing plus the 9,717 placement agent warrants.
- Monitor the filing of the Form S-1 registration statement required within 15 business days of November 19, 2020.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and use of proceeds.